Nakashio S, Iwasawa H, Iino S, Shimada J
Department of Internal Medicine and Laboratory Medicine, St. Marianna University.
Jpn J Antibiot. 1997 Oct;50(10):844-53.
RP 59,500 (Quinupristin-Dalfopristin) is the first semisynthetic injectable streptogramin antimicrobial agent, which is a combination of quinupristin and dalfopristin in a 30:70 ratio. The components of RP 59,500 act synergically to provide bactericidal activity through action at different sites on bacterial ribosomes. In the present study, the antimicrobial activity of RP 59,500 was compared with those of four macrolides (erythromycin, clarithromycin, azithromycin, roxithromycin). Susceptibility testing was carried out by microdilution method on 303 strains of 10 species, especially antibiotic-resistant Gram-positive cocci. RP 59,500 was active against a wide range of Gram-positive cocci including methicillin-resistant Staphylococci and penicillin-resistant Streptococcus pneumoniae. The MICs90 of RP 59,500 against methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis were both 0.25 microgram/ml, although those of four macrolides were higher than 32 micrograms/ml. The MICs90 of RP 59,500 against penicillin-sensitive, -intermediate and -resistant S. pneumoniae were all 0.5 microgram/ml, although those of four macrolides against penicillin-resistant S. pneumoniae were higher than 32 micrograms/ml. RP 59,500 also exhibited equivalent activities to the four macrolides against strains of Streptococcus pyogenes. Streptococcus agalactiae and Moraxella catarrhalis. RP 59,500 exhibited the highest activities against Enterococcus faecalis, Enterococcus faecium and Enterococcus avium strains which are intrinsically resistant to most antimicrobial agents. No cross-resistance was observed between RP 59,500 and the four macrolides, which will merit attention in future clinical trials of the agent. The effect of human serum on the MIC of RP 59,500 was studied with strains of S. aureus, S. epidermidis and E. faecalis. The presence of 20% (V/V) serum had little or no effect on the MIC, although 50% (V/V) serum increased MICs by 4-8 folds. Laboratory-induced resistance to RP 59,500 occurred in a stepwise fashion in broth cultures of S. aureus, S. epidermidis and E. facalis strains and the induction rate was slow and no more than four fold increases were observed. Population analysis was performed on RP 59,500 and the reference macrolides against S. aureus ATCC 25,923 strain. Although low frequencies (less than 0.01%) of resistant sub-population were detected with EM, CAM, AZM and RXM, no RP 59,500-resistant sub-population was detected in this study.
RP 59500(奎奴普丁-达福普汀)是第一种半合成注射用链阳菌素类抗菌药物,它是由奎奴普丁和达福普汀按30:70的比例组合而成。RP 59500的成分通过作用于细菌核糖体的不同位点协同发挥杀菌活性。在本研究中,将RP 59500的抗菌活性与四种大环内酯类药物(红霉素、克拉霉素、阿奇霉素、罗红霉素)进行了比较。采用微量稀释法对10个菌种的303株菌株进行药敏试验,特别是对耐药革兰氏阳性球菌。RP 59500对包括耐甲氧西林葡萄球菌和耐青霉素肺炎链球菌在内的多种革兰氏阳性球菌具有活性。RP 59500对耐甲氧西林金黄色葡萄球菌(MRSA)和表皮葡萄球菌的MIC90均为0.25微克/毫升,而四种大环内酯类药物的MIC90均高于32微克/毫升。RP 59500对青霉素敏感、中介和耐药的肺炎链球菌的MIC90均为0.5微克/毫升,而四种大环内酯类药物对耐青霉素肺炎链球菌的MIC90均高于32微克/毫升。RP 59500对化脓性链球菌、无乳链球菌和卡他莫拉菌菌株的活性也与四种大环内酯类药物相当。RP 59500对大多数抗菌药物固有耐药的粪肠球菌、屎肠球菌和鸟肠球菌菌株表现出最高活性。未观察到RP 59500与四种大环内酯类药物之间的交叉耐药,这在该药物未来的临床试验中值得关注。用金黄色葡萄球菌、表皮葡萄球菌和粪肠球菌菌株研究了人血清对RP 59500 MIC的影响。20%(V/V)血清的存在对MIC几乎没有影响,尽管50%(V/V)血清使MIC增加了4至8倍。在金黄色葡萄球菌、表皮葡萄球菌和粪肠球菌菌株的肉汤培养物中,实验室诱导的对RP 59500的耐药性呈逐步发生,诱导率缓慢,且观察到的增加不超过四倍。对RP 59500和参考大环内酯类药物针对金黄色葡萄球菌ATCC 25923菌株进行了群体分析。虽然用红霉素(EM)、克拉霉素(CAM)、阿奇霉素(AZM)和罗红霉素(RXM)检测到耐药亚群的频率较低(小于0.01%),但在本研究中未检测到对RP 59500耐药的亚群。